Agenus Inc (AGEN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.85 (+8.73%), Market cap $0.15B, P/E ratio 1.75, 52-week low–high $2.77 ~ $7.06.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD
Financial statements, price targets, institutional (13F) holdings and related news for Agenus Inc are updated in real time on BlackAll Trade.
Agenus Inc trades at $7.85 (+8.73%). Real-time quotes and charts are available on BlackAll Trade.
Agenus Inc has a market cap of about $0.15B. Its P/E ratio is 1.75.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an